Smith Douglas Homes (SDHC) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Joe Thomas - SVP of Accounting & FinanceGregory Bennett - President, CEO, Director & Vice ChairmanRuss Devendorf - Executive VP & CFOMike Dahl - Managing Director - Equity ResearchJay McCanless - SVP - Equity Research Conference Call Participants Alex Isaac - Equity Research AnalystRafe Jadrosich - Managing Director & Senior Equity Analyst Operator Thank you for standing by. My name is Tina, and I will be your con ...

Financial Data and Key Metrics Changes - Net sales for Q1 2025 increased by 4.5% to $10 million compared to $9.6 million in the same quarter last year, primarily driven by higher volumes with recurring national customers [19] - Profit for Q1 2025 remained flat at $3.4 million compared to the previous year [20] - Gross margin decreased to 33.9% from 35.6% year-over-year, attributed to higher cost of goods sold as operating capacity and inventory increased [20] - Operating loss for Q1 2025 was $1.7 million, compared to a loss of $700,000 in Q1 2024 [21] - Cash used in operating activities increased to $5.4 million from $2.4 million year-over-year, driven by higher inventory purchases [22] Business Line Data and Key Metrics Changes - The company launched a new multifunctional soda line, which includes flavors like berry bubbly and strawberry vanilla, aimed at expanding its better-for-you portfolio [9][10] - Core product sales saw an expansion at Albertsons Safeway, adding over 1,100 new points of distribution for Reed's Ginger Ale [11] - Successful national offshoot program with Flying Cauldron at Albertsons exceeded internal projections and retail expectations [11] Market Data and Key Metrics Changes - The company secured national distribution in Sprouts Farmers Market and executed resets for all four Reed's functional SKUs across major retailers [10] - Distribution gains were noted in three states at Trader Joe's for classic new alcohol products, reflecting growing demand across core functional and alcohol portfolios [13] Company Strategy and Development Direction - The company is focused on sustainable growth and profitability, with immediate priorities on execution and operational improvements [17] - A strategic shift towards better inventory management and fulfillment rates is underway, supported by a recent capital infusion from a private placement [5][6] - The transition from glass bottles to cans is on track, enhancing cost structure and scalability [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about operational improvements and the potential for profitable growth, emphasizing a commitment to delivering premium, better-for-you beverages [23] - The company anticipates some modest gross margin pressure in Q2 due to seasonal promotion activity and higher trade spend [15] Other Important Information - The company appointed Rude Baker to the board of directors, bringing extensive experience in the beverage industry [8] - The company is actively evaluating alternative suppliers and sourcing strategies to mitigate potential disruptions from global trade dynamics [14] Q&A Session Summary Question: Operating expenses were higher than expected; what should be expected going forward? - Management indicated that the increase in SG&A is due to upfront investments in personnel and marketing to support growth initiatives, and they aim to remain disciplined in managing these expenses [25][27] Question: Will gross margins be pressured in Q2? - Management expects some seasonal compression in gross margins due to trade discounts and additional investments in the functional beverage launch [28] Question: Is there any revenue guidance for the year? - Management refrained from providing specific revenue guidance but emphasized a focus on growth and operating efficiency moving forward [33]

DarioHealth (DRIO) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Speaker0 morning, ladies and gentlemen, and welcome to the DarioHealth First Quarter twenty twenty five Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, 05/14/2025. I would now like to turn the conference over to Kat Paralla, Investor Relations Manager at Dario. Kat, please go ahead. Speaker1 Thank you, ...

Lucid Diagnostics (LUCD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the Lucid Diagnostics First Quarter twenty twenty five Business Update Conference Call. Please note this event is being recorded. I would now like to turn the conference call over to Mr. Matt Reilly, Lucid Diagnostics Senior Director of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Good morning, everyone. Thank you for participating in today's business update call. Joining me to ...

Financial Data and Key Metrics Changes - First quarter revenue was $5.6 million, a decrease from $9.4 million in the same period in 2024, primarily due to the temporary suspension of sales in France and lower investments in sales and marketing [22][5] - Adjusted net operating loss narrowed by 48% to $5.9 million compared to the prior year, with gross margin expanding to 75% from 73% in the prior year and 45% in the previous quarter [5][22] - Cash and cash equivalents at the end of the first quarter were $20.4 million, providing a runway for achieving FDA approval and profitability [25][12] Business Line Data and Key Metrics Changes - Sales and marketing expenses decreased to $3.6 million from $6.1 million in the same period in 2024, driven by increased operating efficiency [23] - Research and development expenses were reduced to $2.6 million from $5.7 million, primarily due to cost reductions related to the IDISSIPPI trial [23] - General and administrative expenses decreased to $5.2 million from $6.4 million, with adjusted expenses at $3.8 million excluding one-time financing costs [24] Market Data and Key Metrics Changes - The company observed over 40% growth quarter over quarter and year over year in its B2B2C model pilot in clinics in Europe [7] - The company expects revenues to ramp as the year progresses with the expansion of the B2B2C model and enhanced sales team onboarding [8] Company Strategy and Development Direction - The company’s 2025 plan focuses on five pillars: a new commercial plan, gaining FDA approval for the Allurion balloon, achieving profitability for the ex-U.S. business, scaling the AI product platform, and resuming commercialization in France [6][7] - The company aims to combine its program with low doses of GLP-1s to create a new standard of care for obesity, targeting a sustained weight reduction of over 20% while maintaining muscle mass [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the efficiency of the new B2B2C model and the potential for significant shareholder value as millions of patients could be treated with the Elerion program [26][27] - The company is optimistic about completing its PMA submission to the FDA by June and is encouraged by the FDA's feedback during the pre-PMA meeting [12][39] Other Important Information - The company has resumed treating patients in France and is in the final phases of updating marketing collateral to reactivate placements [15] - The company does not expect any impact on gross margin from tariffs for the remainder of the year, as most components are manufactured in the U.S. [12][13] Q&A Session Summary Question: Trends in regional markets, especially with the new marketing strategy - Management noted that mature markets for GLP-1s are creating tailwinds, with patients seeking alternatives and the expansion of the direct sales force expected to drive revenue growth [29][30] Question: Timeline and patient enrollment for the GLP-1 trial - Enrollment is expected to begin in the latter half of this year, with a one-year follow-up and a target of at least 75 subjects across multiple sites in Europe [31][32] Question: Design of the trial arms - The trial will focus on validating previous retrospective work with a single arm prospective trial design, leveraging historical data for comparison [33][34] Question: Future gross margin expectations - Management expects margins to remain in the same range as the first quarter, with potential increases as revenues ramp up [35][36] Question: Details on the pre-PMA meeting and next steps - The FDA was receptive to alternative analyses for the control group data, which could strengthen the overall application [39][40] Question: Current adoption of the Elerion program and GLP-1s - There is organic adoption of the combination therapy in the field, with physicians integrating GLP-1s with the Allurion balloon [45][46] Question: Revenue performance cadence for 2025 - Management anticipates steady revenue increases driven by the onboarding of new sales team members and recovery in France [49][50] Question: Expected costs for the prospective study - The prospective trial is not expected to have a material impact on the budget, as existing patient flow and lower costs overseas will be leveraged [51][52] Question: Regulatory strategy regarding expanded labeling - The focus is on the commercial implications of the study, with potential long-term benefits for discussions with regulators and payers [53][54] Question: Procedure growth trends - Procedure volume is stable, with some growth in certain territories, and management expects a recovery in France in the second half of the year [57][58]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company had cash and cash equivalents of $8 million, which is expected to fund operations into the third quarter of 2025 [15] - Research and development expenses for Q1 2025 were $6.1 million, up from $5.1 million in Q1 2024, driven by the ongoing SHIELD II Phase III trial [16] - The net loss for Q1 2025 was $8.3 million, compared to a net loss of $6.4 million in Q1 2024 [16] Business Line Data and Key Metrics Changes - The company is focused on the SHIELD II Phase III trial for DPLEX100, which has recently concluded enrollment with 800 patients, following a recommendation from the Data Safety Monitoring Board [5][6] - The anticipated top line data from the SHIELD II trial is expected by the end of the current quarter [15] Market Data and Key Metrics Changes - The total addressable market for DPLEX100 in the U.S. is estimated to be over 12 million surgeries annually, with approximately 4.4 million being abdominal soft tissue surgeries [11] - The company identified four groups of surgeons as potential users for DPLEX100, indicating a significant market opportunity [12] Company Strategy and Development Direction - The company aims to submit a New Drug Application (NDA) in early 2026, with preparations for regulatory submissions already underway [7][8] - The strategy includes finding a U.S. partner with an existing dedicated hospital product sales force to maximize sales potential [9][13] - An exclusive licensing agreement is already in place with Advanced Pharma for commercialization in Europe [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term prospects of DPLEX100 and the potential to transform the surgical landscape [47] - The company is actively preparing for regulatory submissions and engaging in partnership discussions as they await SHIELD II trial results [8][13] Other Important Information - The company has received Fast Track and Breakthrough Therapy designations for DPLEX100, which may expedite the regulatory process [7] - The company is in advanced discussions with multiple potential partners in the U.S. as they approach pivotal data readout [13] Q&A Session Summary Question: Pricing strategy for DPLEX100 - Management has not finalized the pricing strategy but anticipates an average of 2.5 vials per procedure at a preliminary price of $600 per vial [20] Question: NDA filing requirements - The NDA will consist of three modules, with the company currently finalizing the CMC and preclinical modules [27] Question: Expectations for top line data - The company expects to report both primary and key secondary endpoints upon unblinding the data [32] Question: Inspection readiness for commercial manufacturing - The company is preparing for FDA inspections and plans to conduct several mock inspections prior to the review [40] Question: Comparison of SSI data pre-COVID and post-COVID - The CDC reported a 3% increase in SSIs in 2023 compared to 2022, marking the first uptick since the COVID pandemic [42]

Moleculin Biotech (MBRX) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Speaker0 Good morning. Welcome to the Molecular and Biotech first quarter twenty twenty five update conference call webcast. Question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to your host, Janine Thomas, investor relations. Please go ahead, Janine. Speaker1 Thank you, Rob, and good morning, everyone. At this time, I would like to ...

Financial Data and Key Metrics Changes - For Q1 2025, the company reported net income of $18.2 million, which includes a fair value adjustment of $21.2 million related to contingent earn-out liability [18] - Revenue for Q1 2025 was $87 million, a decrease of $13.8 million or 13.7% from $100.8 million in Q1 2024, primarily due to lower home closings [18][19] - Home closings totaled 252 homes, down from 311 homes in the prior year period [19] - The average sales price for production built homes was approximately $345,000, a 2.9% increase compared to $335,000 in Q1 2024 [19] - Gross profit for Q1 2025 was $14.1 million, down $2 million or 12.4% from $16.1 million in the prior year [20] - Gross margin improved slightly to 16.2% from 16% [20] Business Line Data and Key Metrics Changes - The company delivered 252 homes in Q1 2025, with an average sales price of $345,000, generating home sales revenue of $87 million [4] - Net new orders for Q1 2025 were 296 homes, down from 384 homes in the prior year period [19] - The backlog as of March 31, 2025, stood at 201 homes, representing approximately $75.3 million in value [20] Market Data and Key Metrics Changes - The company noted that affordability continues to be an issue for buyers, necessitating the use of financing incentives [13] - April orders were up 6% year over year, indicating a positive trend in demand [10][13] Company Strategy and Development Direction - The company has undertaken a product refresh and direct cost reduction initiative to improve competitive positioning and profitability [5][6] - A strategic shift towards presold homes is being emphasized, moving away from a high spec home strategy [8][9] - The company plans to open 10 new communities in Q2 and 18 communities in Q3, which are expected to boost sales efforts [15][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term prospects for markets in the Carolinas and Georgia due to favorable housing fundamentals [10] - The company is adapting to shifting market dynamics and remains focused on execution and capital allocation [22] - Management noted that the spring selling season started slowly but showed momentum exiting the quarter into April [22] Other Important Information - The company controlled approximately 7,500 lots as of March 31, 2025, positioning it for future growth [22] - Selling, general and administrative expenses for Q1 were $16.2 million, with adjusted SG&A totaling $14.2 million or 16.3% of revenue [21] Summary of Q&A Session - There were no questions during the Q&A session, and the call concluded with management expressing optimism about the future of the company [24][25]

Financial Data and Key Metrics Changes - The company's GMV for Q1 2025 was $34.2 billion, reflecting a 7% year-over-year increase [12] - Revenue for Q1 2025 was $82.4 million, also up 8% year-over-year [12] - Non-GAAP gross profit margin for Q1 2025 was approximately 50%, with a year-over-year decline attributed to ramping up new merchants in newer categories [16] - Positive adjusted EBITDA of $1.3 million was achieved in Q1 2025, marking the sixth consecutive quarter of positive adjusted EBITDA [18] - The company ended Q1 2025 with approximately $357 million in cash, deposits, and investments, carrying zero debt [18] Business Line Data and Key Metrics Changes - New product revenue growth was up approximately 190% year-over-year, indicating strong traction of the platform [8] - The two largest categories, Tickets and Travel and Fashion and Luxury, each grew in the mid-teens range year-over-year [12] - The money transfer and payments category achieved approximately 90% year-over-year growth in Q1 2025, driven by new merchant activity [13] - The home category contracted by 74% year-over-year, contributing to a 5% decline in the U.S. [14] Market Data and Key Metrics Changes - APAC grew approximately 70% and Outer Americas (Canada and Latin America) grew approximately 13% in Q1 2025, primarily due to new and upsell activity [15] - Eight of the top ten new logos won during Q1 2025 were headquartered outside the U.S., indicating a focus on international growth [11] Company Strategy and Development Direction - The company is focused on expanding its top-of-funnel efforts to generate more pipeline and converting that pipeline into new business [5] - There is a strategic investment in machine learning capabilities to enhance performance for merchants [9] - The company aims to maintain a non-GAAP gross profit margin between 52% to 53.5% for the full year [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of consumers despite macroeconomic uncertainties [10] - The company maintains its revenue guidance of $333 million to $346 million for 2025, reflecting a balanced view of risks and opportunities [20] - Management noted that the global go-to-market strategy is starting to pay off, with more opportunities diversified outside the U.S. [26] Other Important Information - The company repurchased 4.1 million shares for approximately $20.7 million in Q1 2025, reflecting a commitment to managing dilution [19] - The company expects approximately $30 million of positive free cash flow in 2025, with most cash flow generation anticipated in the second half of the year [19] Q&A Session Summary Question: Impact of product roadmap execution on growth confidence - Management highlighted strong pipeline growth and the effectiveness of their platform in driving new business opportunities [25] Question: Timeline for gross margin stabilization - Management encouraged looking at gross margins on an annual basis, with expectations for improvements as large client wins ramp up [29] Question: Update on mid-tier market strategy - Management indicated that while there is potential in the mid-tier market, current strength is still focused on enterprise-level clients [34] Question: Competitive landscape comparison with Stripe - Management emphasized the advantages of their data capabilities over gateway solutions like Stripe, which have more limited data access [40] Question: Industry growth rate compared to GMV growth - Management noted that their growth in certain categories, like travel, has outperformed broader industry metrics, indicating share gains [44] Question: Growth mix between new logos and existing base - Management indicated that new logo growth is slightly higher than expected, while dollar retention rates remain around 100% [62]

Financial Data and Key Metrics Changes - 2024 was a transformative year for the company, marked by decisive actions that positioned it for long-term profitable growth and value creation for shareholders [5] - The company successfully completed the sale of Worldpac for $1.5 billion, strengthening its balance sheet and streamlining operations [5] Business Line Data and Key Metrics Changes - The company made the difficult decision to rationalize its store and distribution center footprint, with over 75% of the revised store footprint in designated market areas where it holds the number one or two position based on store density [6] - Strategic investments were made to enhance competitive position, reduce turnover, and improve customer service [6] Market Data and Key Metrics Changes - The company retained the Carquest Canada business, which resembles the US blended box model and offers additional runway for long-term growth [5] Company Strategy and Development Direction - A strategic plan was introduced focusing on three fundamental areas: merchandising excellence, supply chain, and store operations [7] - The company is focused on execution and has a renewed emphasis on customer-centric strategies [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic direction and the urgency of execution as the company looks to 2025 and beyond [7] - The management team has been strengthened with leaders possessing deep retail expertise and strong functional knowledge [6] Other Important Information - The company held its annual meeting virtually, allowing shareholders to submit questions via a Q&A tool [2] - A quorum was confirmed with 92.23% of outstanding shares present or represented [12] Q&A Session Summary Question: Inquiry about business operations - The company plans to address all industry and business matters in the upcoming earnings call scheduled for May 22 [24][25]